Department of Ophthalmology, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
Eur J Ophthalmol. 2023 Jul;33(4):NP101-NP104. doi: 10.1177/11206721221112802. Epub 2022 Jul 11.
To report a case of cytomegalovirus (CMV) retinitis complicated with ganciclovir-related myelosuppression, which was successfully managed with intravenous (IV) ganciclovir and CMV immunoglobulin (CMVIG) therapy.
Observational case report.
A 51-year-old male with follicular type non-Hodgkin lymphoma post hematopoietic stem cell transplantation (HSCT) developed vision-threatening retinitis. polymerase chain reaction (PCR) of the aqueous humour showed positive for CMV. Despite myelosuppression occurred during IV ganciclovir therapy, the retinitis resolved and intraocular CMV viral load significantly improved after CMVIG therapy.
Combined IV ganciclovir treatment and CMVIG therapy can significantly improve visual outcome and reduce intraocular CMV viral load in vision-threatening CMV retinitis.
报告一例合并更昔洛韦相关性骨髓抑制的巨细胞病毒（CMV）视网膜炎，经静脉（IV）更昔洛韦和 CMV 免疫球蛋白（CMVIG）治疗成功治疗。
观察性病例报告。
一名 51 岁男性，患有滤泡型非霍奇金淋巴瘤，接受造血干细胞移植（HSCT）后发生威胁视力的视网膜炎。房水聚合酶链反应（PCR）检测 CMV 呈阳性。尽管在 IV 更昔洛韦治疗期间发生骨髓抑制，但在 CMVIG 治疗后，视网膜炎消退，眼内 CMV 病毒载量显著改善。
联合 IV 更昔洛韦治疗和 CMVIG 治疗可显著改善威胁视力的 CMV 视网膜炎的视力预后，并降低眼内 CMV 病毒载量。
